Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Qiming to Raise $250 Million for Second US Dollar Healthcare Fund

publication date: Feb 1, 2019

China's Qiming Venture Partners announced plans to raise $250 million for its second US dollar healthcare fund, aimed at investing in US early-stage life science companies. One year ago, Qiming closed its first US Healthcare Fund at $120 million, part of a larger $1.4 billion fundraising that also included two all-sectors funds. Qiming has invested in nearly 80 life science companies, including AmoyDx, TigerMed, Gan & Lee, Frontage and Zai Lab. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital